ASX-listed biotech Chimeric Therapeutics, a clinical stage cell-therapy company has pocketed a research and development tax refund worth more than $3 million. The company says the refund is in recognition of its activities during the 2022 financial year and the rebate will provide important funding for continued development of its portfolio of cell therapies that tackle cancer.
14/02/2023 - 18:48
Chimeric pockets tax refund for cancer-fighting work
By Matt Birney
14/02/2023 - 18:48
Related Data & Insights
-
Chimeric TherapeuticsClosing price for the last 90 trading daysPowered by Morningstar ®
-
Rank Company Revenue 864th Chimeric Therapeutics $4.9m 1020th Environmental Clean Technologies $838k 1021st Sunrise Energy Metals $830k 1023rd Rightcrowd $805k 1024th TALI Digital $784k 1328 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Data & Insights
Mentioned Organisations
Related Articles
Subscribe today for award-winning, unbiased and trusted journalism
Subscription OptionsX